Head to Head Review: CymaBay Therapeutics (NASDAQ:CBAY) versus REGENXBIO (RGNX)
CymaBay Therapeutics (NASDAQ: CBAY) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitabiliy, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
This is a breakdown of current recommendations and price targets for CymaBay Therapeutics and REGENXBIO, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CymaBay Therapeutics currently has a consensus price target of $13.80, suggesting a potential upside of 92.74%. REGENXBIO has a consensus price target of $37.50, suggesting a potential upside of 101.61%. Given REGENXBIO’s higher probable upside, analysts plainly believe REGENXBIO is more favorable than CymaBay Therapeutics.
Risk & Volatility
CymaBay Therapeutics has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Comparatively, REGENXBIO has a beta of -0.73, suggesting that its share price is 173% less volatile than the S&P 500.
This table compares CymaBay Therapeutics and REGENXBIO’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
25.4% of CymaBay Therapeutics shares are held by institutional investors. Comparatively, 67.2% of REGENXBIO shares are held by institutional investors. 15.1% of CymaBay Therapeutics shares are held by insiders. Comparatively, 17.0% of REGENXBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares CymaBay Therapeutics and REGENXBIO’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|CymaBay Therapeutics||$4.79 million||42.98||-$20.41 million||($1.05)||-6.82|
|REGENXBIO||$4.65 million||123.28||-$75.96 million||($2.80)||-6.64|
CymaBay Therapeutics has higher revenue and earnings than REGENXBIO. CymaBay Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
CymaBay Therapeutics beats REGENXBIO on 8 of the 14 factors compared between the two stocks.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.